^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Cancer

    Related cancers:
    1m
    Metachronous Colorectal Carcinomas and Pancreatic Metastasis in Clinically Suspected Lynch Syndrome: An 18-Year Oncologic Course. (PubMed, Cureus)
    The findings favored metastatic colorectal carcinoma involving the pancreas in the setting of clinically suspected Lynch syndrome. This case emphasizes the importance of clinicopathologic correlation, cautious interpretation of MMR deficiency, and long-term multidisciplinary surveillance.
    Journal
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    1m
    Phenylalanine Hydroxylase as a Prognostic Marker in Pancreatic Cancer: Insights into Tumor Metabolism and Immune Microenvironment. (PubMed, Curr Med Chem)
    This study is the first to reveal PAH as a metabolic immunomodulator and an independent prognostic factor in postoperative PC patients. PAH may affect prostate cancer outcomes by altering the tumor microenvironment.
    Journal
    |
    CD8 (cluster of differentiation 8)
    1m
    KIF20A in Human Malignancies: Oncogenic Mechanisms and Therapeutic Targeting Strategies. (PubMed, Mini Rev Med Chem)
    It also discusses recent advances in targeting strategies. The review provides insights for developing effective anti-cancer therapies.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • CCNB1 (Cyclin B1) • KIF20A (Kinesin Family Member 20A)
    1m
    Comprehensive computer analysis of an intratumoral viable biological agent as a systemic multi-mechanistic therapeutic strategy for pancreatic cancer treatment. (PubMed, In Silico Pharmacol)
    This systems-level framework provides mechanistic rationale for clinical investigation of intratumoral S. boulardii as adjuvant PDAC therapy. The online version contains supplementary material available at 10.1007/s40203-026-00685-6.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • LDHA (Lactate dehydrogenase A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL10 (Interleukin 10) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • TLR4 (Toll Like Receptor 4) • IL17A (Interleukin 17A) • TLR2 (Toll Like Receptor 2)
    1m
    Intraductal papillary mucinous neoplasm-derived pancreatic cancer of the ventral duct in patient with pancreas divisum: a case report. (PubMed, J Surg Case Rep)
    Due to high-risk stigmata, the patient underwent a Whipple procedure and was found to have a 3.5-cm pancreatic cancer arising from an IPMN of the ventral duct. Given the risk of progression, patients with pancreas divisum who develop ventral duct IPMN require careful surveillance and timely escalation of care when appropriate.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    1m
    Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome. (PubMed, Clin Case Rep)
    Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan...The role of microsatellite instability (MSI) as a screening marker, and personalized treatment approaches like immunotherapy for dMMR tumors. Understanding these correlations may assist in early discovery, surveillance, and customized treatment for patients dealing with LS-associated malignancies.
    Journal • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial. (PubMed, J Clin Oncol)
    Zenocutuzumab demonstrated clinically meaningful and durable antitumor activity with a favorable safety profile in patients with advanced NRG1+ cholangiocarcinoma.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1)
    |
    NRG1 fusion
    |
    Bizengri (zenocutuzumab-zbco)
    1m
    Leveraging Carnitine-functionalized Lipid Nanocarrier based Targeted Delivery of A1874 PROTAC for Glioblastoma. (PubMed, Pharm Res)
    PRONano is brain-targeted, rationally designed nanoformulation which can overcome major A1874 delivery constraints. This strategy augmented PROTAC delivery and therapeutic potential in GBM, supporting future preclinical development.
    Journal
    |
    BRD4 (Bromodomain Containing 4)
    |
    temozolomide
    1m
    SGNBB228-001: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=41, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons. The decision was not based on any safety concerns.
    Trial termination
    |
    PF-08046049
    1m
    A HRH1-YAP1 feedback loop drives pancreatic cancer progression and predicts therapeutic response. (PubMed, Oncol Lett)
    Patients in the high-risk group exhibited characteristics associated with worse outcomes, including KRAS mutations, chemoresistance, an immunosuppressive microenvironment and reduced responsiveness to immunotherapy. The present study establishes HRH1 as a novel therapeutic target in PDAC and proposes the repurposing of fexofenadine as a promising strategy to disrupt the oncogenic HRH1-YAP1 feedback loop.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • YAP1 (Yes associated protein 1) • ITGA2 (Integrin Subunit Alpha 2) • ITGB5 (Integrin Subunit Beta 5) • MAML2 (Mastermind Like Transcriptional Coactivator 2) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta)
    |
    KRAS mutation
    1m
    PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells. (PubMed, Mol Ther Oncol)
    This may explain why PARP7i were more effective as monotherapy in PANC-1 cells, promoting NK cell activation. These findings support further evaluation of PARP7i in PDAC in combination with radiotherapy or as monotherapy, depending on the immunosuppressive effects of radiation.
    Journal • PARP Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STING (stimulator of interferon response cGAMP interactor 1) • TIPARP (TCDD Inducible Poly(ADP-Ribose) Polymerase)
    |
    KRAS mutation
    1m
    1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, University of Maryland, Baltimore | Trial completion date: Dec 2027 --> Dec 2026
    Trial completion date
    |
    gemcitabine